James River Group Holdings Ltd
Change company Symbol lookup
Select an option...
JRVR James River Group Holdings Ltd
DIDIY DiDi Global Inc
SHOP Shopify Inc
NTR Nutrien Ltd
APGN Apexigen Inc
NSRGY Nestle SA
WE WeWork Inc
NOK Nokia Oyj
HLNE Hamilton Lane Inc
SAL Salisbury Bancorp Inc
Go

Financials : Insurance | Small Cap Value
Based in Bermuda
Company profile

James River Group Holdings, Ltd. owns and operates a group of specialty insurance and reinsurance companies. It operates in four segments: Excess and Surplus Lines, Specialty Admitted Insurance, Casualty Reinsurance and Corporate and Other. Excess and Surplus Lines segment offers commercial excess and surplus lines liability and property insurance. Specialty Admitted Insurance segment approaches the insurance market in two ways: as a risk bearing underwriter, and as a fronting company. Its risk bearing underwriting is focused on niche classes within the insurance markets, such as workers’ compensation coverage for residential contractors, light manufacturing operations, transportation workers and healthcare worker. Casualty Reinsurance segment primarily provides proportional and working layer casualty reinsurance to third parties (primarily through reinsurance intermediaries). Corporate and Other segment consists of the management and treasury activities of its holding companies.

Price
Delayed
$25.56
Day's Change
-0.49 (-1.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
26.02
Day's Low
25.48
Volume
(Light)

Today's volume of 48,042 shares is on pace to be much lighter than JRVR's 10-day average volume of 168,410 shares.

48,042

Stifel reiterates sell rating on Aurora Cannabis after its acquisition of TerrFarma

8:34 am ET March 23, 2022 (MarketWatch)
Print

Stifel analyst W. Andrew Carter on Wednesday reiterated his sell rating for Aurora Cannabis Inc. (ACB.T) after the Canadian cannabis company announced plans to buy TerraFarma Inc., the parent company of craft cultivator Thrive Cannabis, for up to C$68 million ($54 million), including C$38 million plus two earnouts totaling C$30 million. Carter said the Thrive acquisition supports the company's premium strategy and marks a step toward its goal to generate positive Ebitda. "With revenue yet to stabilize, growth uninspiring, and the convertible due 2024 looming large, we believe the shares will continue to be under pressure until the valuation fully rightsizes for the challenges ahead," Carter said. Shares of Aurora Cannabis are down 32% so far in 2022, compared to a drop of 15.2% by the Cannabis ETF (THCX).

-Steve Gelsi

	

(END) Dow Jones Newswires

March 23, 2022 08:34 ET (12:34 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.